A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks  by Cravo, Ana S. et al.
lable at ScienceDirect
Regulatory Toxicology and Pharmacology 81 (2016) S1eS14Contents lists avaiRegulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate/yrtphA randomised, parallel group study to evaluate the safety proﬁle of an
electronic vapour product over 12 weeks
Ana S. Cravo a, *, Jim Bush b, Girish Sharma c, Rebecca Savioz d, Claire Martin d,
Simon Craige a, Tanvir Walele a
a Fontem Ventures, Barbara Strozzilaan 101, 1083 HN, Amsterdam, Netherlands
b Covance Clinical Research Unit, Hyde Street, Leeds, LS2 9LH, UK
c Simbec Research, Merthyr Tydﬁl, CF48 4DR, UK
d Clinopsis S.A., Jardins 6, 1426, Concise, Switzerlanda r t i c l e i n f o
Article history:
Received 2 July 2016
Received in revised form
26 September 2016
Accepted 15 October 2016









Biomarkers of biological effect
Withdrawal symptoms
Smoking urgesAbbreviations: AE, adverse event; BoBE, biomark
biomarker of exposure; BP, blood pressure; CC, conv
dence interval; COHb, carboxyhaemoglobin eCO, exh
cigarettes per day; ECG, electrocardiogram; EoS, en




0273-2300/Crown Copyright © 2016 Published by Else
4.0/).a b s t r a c t
A randomised, parallel group clinical study was performed to evaluate the safety proﬁle of an e-vapour
product (EVP; 2.0% nicotine) in smokers of conventional cigarettes (CCs) switching to use the EVP for 12
weeks. During the study, no clinically signiﬁcant product-related ﬁndings were observed in terms of vital
signs, electrocardiogram, lung function tests and standard clinical laboratory parameters. Adverse events
(AEs) reported by EVP subjects were more frequent during the ﬁrst week after switching to the EVP. The
frequency of AEs reduced thereafter and out of a total of 1515 reported AEs, 495 were judged as being
related to nicotine withdrawal symptoms. The most frequently stated AEs were headache, sore throat,
desire to smoke and cough reported by 47.4, 27.8, 27.5 and 17.0% of subjects, respectively. Only 6% of AEs
were judged as probably or deﬁnitely related to the EVP. Additional observations in EVP subjects included
a decrease in the level of urine nicotine equivalents by up to 33.8%, and decreases in the level of three
biomarkers of exposure to toxicants known to be present in CC smoke (benzene, acrolein and 4-
[methylnitrosamino]-1-[3-pyridyl]-1-butanone). The decrease in nicotine equivalents coincided with an
increase in nicotine withdrawal symptoms, measured by a questionnaire, which subsided after two
weeks. The data presented here shows the potential EVPs may offer smokers looking for an alternative to
CCs.
Crown Copyright © 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ﬁrst electronic vapour products (EVPs), such as e-cigarettes,
were launchedmore than a decade ago, and since then their market
has constantly increased and diversiﬁed (Zhu et al., 2014).
EVPsmay be used by smokers of conventional cigarettes (CCs) as
a means to reduce, replace or stop smoking (Berg et al., 2015;
Dockrell et al., 2013); however, there is ongoing debate with
regards to their efﬁcacy, long-term safety and how such products
should be regulated. EVPs are battery-powered devices that deliverer of biological effect; BoE,
entional cigarettes; CI, conﬁ-
aled carbon monoxide; CPD,
d of study; EVP, electronic
equivalents.
com (A.S. Cravo).
vier Inc. This is an open access artian aerosol (popularly referred to as “vapour”) to users from an e-
liquid. E-liquids typically contain glycerol and propylene glycol (PG)
in varying proportions from which the aerosol is generated and
may contain nicotine and various ﬂavours. Most EVPs do not
contain tobacco, do not require combustion, or generate side-
stream smoke. To date, there is data available in the published
literature on the chemical composition of e-liquids and aerosols
(Etter et al., 2013; Farsalinos et al., 2015a; Goniewicz et al., 2014;
Tayyarah and Long, 2014), the efﬁcacy of EVPs to deliver nicotine
to users (D'Ruiz et al., 2015; Etter, 2016; Farsalinos et al., 2014,
2015b; Hajek et al., 2014), and on the health and subjective ef-
fects of EVPs when used in the short-term (Dicpinigaitis et al., 2016;
Farsalinos, 2012; Flouris et al., 2012; van Staden et al., 2013;
Vansickel et al., 2010; Vardavas et al., 2012).
Studies on the chemistry of the aerosol generated by EVPs have
shown that it tends to contain fewer and lower amounts of selected
harmful and potentially harmful constituents (HPHCs) than those
typically found in CC smoke. For example, many carbonyls, tobaccocle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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present in CC smoke were not detectable in the machine-generated
aerosol of several different EVPs (Tayyarah and Long, 2014). A
number of studies have demonstrated that this also results in
reduced exposure to these toxicants in users. For example, the urine
collected from EVP users has been shown to contain signiﬁcantly
lower amounts of selected toxicants and carcinogenic metabolites
than the urine of CC smokers (Hecht et al., 2015). Moreover, both
exclusive (EVP only) and dual (concomitant use of CCs and EVPs)
users have been shown to have reduced levels of the primary
metabolite of acrolein in urine, four weeks after switching from
exclusive CC use (McRobbie et al., 2015).
To date, evidence regarding the safety of mid- and long-term
EVP use is available from two randomised trials (one of which is
published in two separate articles) (Bullen et al., 2013; Caponnetto
et al., 2013; Farsalinos et al., 2016) and from three prospective
cohort studies (Manzoli et al., 2016; Polosa et al., 2011, 2014) con-
ducted in Italy and in New Zealand. These studies followed par-
ticipants using EVPs for 6, 12 or 24 months, and identiﬁed few, if
any, persistent adverse health effects related to EVP use. The main
focus of those studies was on smoking cessation or reduction, and
none of them assessed exposure to potential toxicants in parallel
with safety.
We recently conducted an evaluation of a closed system EVP
prototype, which included a nicotine pharmacokinetic (PK) study,
and an assessment of safety and subjective effects in healthy,
established smokers of CCs, using the product over a short-term
period (5-day study) (Walele et al., 2016a, 2016b). In the present
study, we evaluated the safety and subjective effects when the
same closed system EVP prototype was used by established
smokers of CCs for 12 weeks. The safety evaluation included
monitoring of adverse events (AEs), vital signs, electrocardiogram
(ECG) parameters, lung function tests and clinical laboratory pa-
rameters. In particular, parameters reported to change following CC
smoking (Frost-Pineda et al., 2011; Lowe et al., 2009; Ludicke et al.,
2015), such as the blood level of white blood cells and high-density
lipoprotein cholesterol, were also evaluated and referred to as
biomarkers of biological effect (BoBE). We also assessed whether
EVP use was associated with reduced exposure to selected HPHCs,
by measuring the level of biomarkers of exposure (BoE) to these
HPHCs in urine, blood and exhaled breath.
2. Material and methods
2.1. Study design
The study was designed as an open-label, randomised, parallel
group, clinical trial conducted in two centres in the UK (Covance
Clinical Research Unit Ltd, Leeds and Simbec Research Ltd,Wales). A
total of 420 adult smokers of CCs were planned to be enrolled (210
subjects per centre, recruited from the local population). The study
was performed in ambulatory settings, however, a subgroup of 40
subjects at the Covance centre (referred to as Cohort 2) stayed in
conﬁnement for the ﬁrst study week. Subjects requiring only the
ambulatory visits were labelled Cohort 1. The conﬁnement
component was included in order to monitor and evaluate study
outcomes in subjects using exclusively the allocated products.
Subjects in both cohorts were randomised in a 3:1 ratio to either
switching to using an EVP prototype or continuing to smoke their
own CC brand for a total of 12 weeks.
All relevant study documents were approved by the South East
Wales Research Ethics Committee on 13 December 2013. The study
is registered at the US National Institutes of Health (ClinicalTrials.
gov) #NCT02029196. All procedures were performed in accor-
dance with the International Conference on Harmonisation (ICH)Harmonised Tripartite Guideline for Good Clinical Practice (GCP).
Written informed consent was obtained from each subject before
any procedures or assessments commenced prior to participating
in the study.
2.2. Study population
In order to be included in the study, subjects of either gender
had to be between 21 and 65 years of age, with a body mass index
in the range of 18e35 kg/m2, to have smoked 5e30 cigarettes per
day (CPD) for at least one year (self-reported) and to be in good
health (as determined by a medical history, a physical examination,
a 12-lead electrocardiogram [ECG], lung function tests and clinical
laboratory evaluations). Subjects had to be established smokers, as
determined by urinary cotinine levels (a score of 3 and above on a
NicAlert™ test strip [Nymox Pharmaceutical Corporation] was
considered positive), and exhaled carbon monoxide (eCO) levels
(measured through Bedfont Micro þ Smokerlyzer; a readout
greater than 6 ppm was considered positive). Subjects who had
taken or received any form of nicotine replacement therapy (NRT),
snuff, or chewing tobaccowithin 14 days of the pre-study screening
visit, or intended to use it during the study, were excluded. Subjects
were also excluded if they were trying to stop smoking or were
considering quitting, if they had a clinically signiﬁcant illness such
as bronchitis or a history of any clinically signiﬁcant disorders such
as cardiovascular, neurological or respiratory disorders, and also if
they had a history of drug or alcohol abusewithin two years prior to
the study start. Female subjects whowere of childbearing potential
and who were not willing to use an acceptable contraceptive
method for the duration of the study were also excluded. Prior or
concomitant use of EVPs was not an exclusion criteria.
2.3. Products used in this study
The EVP prototype used in this study was developed by Fontem
Ventures B.V. (Amsterdam, the Netherlands); an illustration is
available in Walele et al. (2016a). It consisted of a rechargeable
battery (voltage range of 3.0e4.2 V), an atomiser and a capsule
(small cartridge) containing e-liquid. The capsules were replaceable
and the battery and atomiser were reusable. Thewick consisted in a
ﬁberglass string, and the heating coil was a nichrome resistance
wire. The base components of the e-liquids used were PG (70e75%
w/w), glycerol (18e20% w/w) and water (5% w/w). Subjects rand-
omised to the EVP arm could choose between two different e-liq-
uids, which differed solely in their ﬂavour: a menthol-ﬂavoured e-
liquid with 2.0% nicotine (2.7 mg nicotine/capsule) and a tobacco-
ﬂavoured e-liquid with 2.0% nicotine (2.7 mg nicotine/capsule).
Each capsule was expected to provide 40 to 60 puffs, depending on
the user's pufﬁng behaviour.
Subjects randomised to the CC arm used their own usual CC
brand (representative of the UK market; mean ISO nicotine yield
0.81 mg and mean ISO tar yield 9.2 mg).
2.4. Study schedule and procedures
Subjects signed the informed consent form and were allowed to
familiarise themselves with the EVP at the screening visit (subjects
could see and try the EVP). Enrolled subjects then returned to the
study site for a second visit within the twoweeks prior to the study
start to select which EVP ﬂavour they preferred should they be
randomised to the EVP, and to collect product use diary cards and
urine collection containers. Cohort 1 subjects came to the site for a
baseline visit (Day -1) and then at Weeks 1, 2, 4, 6, 8, 10 and 12 (end
of study - EoS). Cohort 2 subjects were admitted to the centre
(Covance, Leeds) on Day -2, and stayed in conﬁnement until Day 6.
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reported to the centre as subjects in Cohort 1.
Baseline procedures were conducted on Day -2 and Day -1 for
Cohort 2 subjects, and on Day -1 for Cohort 1 subjects. Baseline
procedures included:
 conﬁrmation of eligibility criteria and veriﬁcation of smoking
status by measuring the urinary cotinine levels in a spot urine
sample;
 eCO levels and blood carboxyhaemoglobin (COHb) levels;
 body weight and physical examination;
 safety assessment, which included vital signs, a lung function
test and a 12-lead ECG;
 blood and urine sampling for haematology, clinical chemistry
and urinalysis parameters (Table 1);
 blood sampling for determination of trans-30-hydroxycotinine/
cotinine ratio;
 pregnancy test for females of childbearing potential;
 administration of the revised Minnesota Nicotine Withdrawal
Scale (MWS-R) questionnaire to document nicotine withdrawal
symptoms (Hughes, 2007) and the Brief Questionnaire of
Smoking Urges (QSU-Brief), to measure smoking desire (Cox
et al., 2001);
 randomisation of subjects to the EVP or CC arm.
At baseline, subjects randomised to the EVP arm attended aTable 1
Study outcome measures.
Outcome measure Details of measured parameters
Primary outcomes (safety)
Adverse events (AEs) Monitoring of AEs along with severity grades
report AEs on their diary cards, and were sub
symptoms reported on the MWS-R questionn
Medical Dictionary for Regulatory Activities (
nicotine withdrawal, with an onset within th
Vital signs Sitting systolic and diastolic blood pressure, p
minutes.
12-lead ECG 10-s strips, after the subject has been resting f
QTcF, QRS duration. A physician performed a
abnormal-not clinically signiﬁcant (NCS) or a
Lung function tests Sitting spirometry to measure forced vital cap
and forced expiratory volume in one second
Acceptable repeatability is determined accord
guidelines (Miller et al., 2005).
Haematology White blood cell count (WBC), red blood cell
haemoglobin (MCH), mean cell haemoglobin
Clinical biochemistry Blood levels of aspartate aminotransferase (A
transferase (GGT), sodium, potassium, chlorid
creatinine, total protein, albumin, cholestero
Urinalysis pH, protein, glucose, ketones, urobilinogen, b
Secondary outcomes
Biomarkers of exposure in urine Amount excreted in 24-h urine (Ae24h) for: n
glucuronide, trans 3’-hydroxycotinine and tr
(NNAL þ NNAL-glucuronide).
Other biomarkers of exposure Exhaled CO, blood COHb
Biomarkers of biological effect Haemoglobin, PCV, RBC, WBC and cholestero
MWS-R scores The questionnaire was modiﬁed to include o
questions on behaviour) and the extended tot
frustrated, depressed, restless, insomnia) we
maximum of 60.
QSU-brief scores Ten statements such as “I have a desire for a ci
(strongly agree). Factor 1 scores (sum of ques
questions 2, 4, 5, 8, and 9, for anticipation of r
questions) were calculated. Total scores may
Abbreviations: CO: carbon monoxide; COHb: carboxyhaemoglobin; MWS-R: revised Minn
QTcB: QT interval corrected for heart rate using Bazett's formula; QTcF: QT interval correct
density lipoprotein; NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (biomarker
butanone, or NNK); PG: propylene glycol; S-PMA: s-phenyl mercapturic acid (biom
(biomarker of exposure for acrolein).face-to-face sessionwhere theywere trained on how to use the EVP
properly. At baseline, EVP subjects were also provided with an EVP
device and with sufﬁcient capsules to last for the duration of the
study. They were asked to start using the EVP from Day 1.
Vital signs, 12-lead ECG, lung function, clinical chemistry and
clinical haematology were checked on Day 6 (Cohort 2 subjects
only) and during Weeks 2, 4, 8 and 12 (all subjects). Body weight
was measured on Weeks 4, 8 and 12 for all subjects. Spot urine
samples were taken for urinalysis on Day 6 (Cohort 2 only) and in
Week 12 (all subjects). Subjects collected and returned 24-h urine
samples (acquired the day before the visit and kept in the fridge or
in a cool bag) for biomarker analysis on Days 1e6 (Cohort 2) and in
Weeks 4, 8 and 12 (all subjects). eCO and blood COHb were ana-
lysed at every study visit for both cohorts. AEs were also monitored
at every study visit. Subjects answered both the MWS-R and QSU-
Brief questionnaires on Days 1, 3 and 5 (Cohort 2 only) and in
Weeks 1, 2, 4, 6, 8, 10 and 12 (all subjects). All subjects were
requested to record the number of CCs smoked and capsules used
throughout the study in diary cards. Diary cards, as well as used
capsules, were collected at each visit and subjects were reminded
to be compliant to their assigned product.
Fasting was not required for any study visit, except a 6-h fast
prior to the screening visit. Subjects were not required to be
abstinent from smoking or using the EVP prior to any study visit.
Subjects were not allowed to use alcohol 48 h prior to the baseline
visit, and fromwaking time on the other study visit days. On Weekand relationship to product were assessed throughout the study. Subjects could
ject to open questioning on how they felt, at each visit. Moderate and severe
aire were also listed as AEs (with the same severity). All AEs were coded using the
MedDRA), version 16.1, 2013. AEs judged by the investigator as being related to
e two ﬁrst study weeks, were identiﬁed.
ulse rate and oral temperature, after the subject has been resting for at least ﬁve
or at least ﬁveminutes: heart rate (60/R-R duration), PR interval, QT interval, QTcB,
clinical assessment of each 12-lead ECG, and categorised them as normal,
bnormal-clinically signiﬁcant (CS).
acity (FVC), forced expiratory ﬂow 25%e75% (FEF25-75), peak expiratory ﬂow (PEF)
(FEV1). The best of three acceptable attempts is taken as the true measure.
ing to the American Thoracic Society and European Respiratory Society (ATS/ERS)
count (RBC), haemoglobin, haematocrit (PCV), mean cell volume (MCV), mean cell
concentration (MCHC), platelet count, differential WBC.
ST), alanine aminotransferase (ALT), alkaline phosphatase, gamma-glutamyl
e, calcium, inorganic phosphate, glucose, urea nitrogen (BUN), total bilirubin,
l (HDL, LDL, and total).
lood and speciﬁc gravity
icotine equivalents (NEQs: nicotine, cotinine, nicotine-N-glucuronide, cotinine-N-
ans 3’-hydroxycotinine glucuronide); S-PMA; 3-HPMA; PG; total NNAL
l (LDL, HDL and total)
nly the 15 questions of subject's part. The core total scores (sum of the ﬁrst nine
al scores (sum of all 15 questions) were calculated. Symptoms (e.g. angry, irritable,
re rated from 0 (none) to 4 (severe). Extended total scores may range from 0 to a
garette right now”, were rated by a number ranging from 1 (strongly disagree) to 7
tions 1, 3, 6, 7, and 10 for desire and intention to smoke), Factor 2 scores (sum of
elief from negative effects with urgent desire to smoke) and total scores (sum of all
range from 0 to a maximum of 70.
esota Nicotine Withdrawal Scale; QSU-Brief: Brief Questionnaire of Smoking Urges;
ed for heart rate using Fridericia's formula; HDL: high-density lipoprotein; LDL: low-
of exposure for the tobacco nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-
arker of exposure for benzene); 3-HPMA: 3-hydroxypropyl mercapturic acid
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procedures mentioned above. After all procedures were completed,
subjects were provided full verbal smoking cessation advice by the
investigator.
2.5. Study outcomes
The primary outcomes measured in this study were the safety
parameters, which included vital signs, AEs, ECGs, lung function
tests and clinical laboratory parameters. The secondary outcomes
included a determination of the level of selected BoE in urine
(HPHCs typically found in CC smoke, and for which a BoE in urine
has been identiﬁed), the level of selected BoBE in blood, and
smoking desire and withdrawal symptoms measured by ques-
tionnaires. Primary and secondary outcome measures are detailed
in Table 1.
2.6. Sample size and assignment to study arm
The sample size for the EVP arm was determined according to
the Council for International Organizations of Medical Sciences
(CIOMS) guideline indicating that in order to have a power of 95% to
detect AEs which occur in the study population at a frequency of 1%
(common AEs), an exposed population of 300 subjects would be
necessary (Dollery and Bankowski, 1983). A total of 100 subjects
were planned to be enrolled into the CC study arm as a control. To
allow for an anticipated dropout rate of 5%, a total of 420 subjects
were planned to be enrolled.
Randomisation was performed using an Interactive Web
Response System (IWRS; Almac Clinical Technologies). Age was
selected as a stratiﬁcation factor (21e39 years or 40 years), as
frequency and intensity of AEs can be affected by age. The stratiﬁed
randomisation ensured balanced allocation of both age groups to
the two study arms. In addition, the ﬁrst 40 subjects that agreed to
a week-long conﬁnement period were assigned to Cohort 2.
In general, data was stratiﬁed by study arm, i.e. EVP vs CC. The
following additional stratiﬁcation criteriawere usedwhere deemed
appropriate: age (21e39 vs  40 years), sex, baseline smoking
history (low: 5e10 vs medium: 11e20 vs high: 21e30 self-reported
CPD at baseline) and EVP compliance (EVP-compliant vs less EVP-
compliant). EVP compliance was deﬁned as being compliant for
80% or more of the study days. A subject was deemed compliant on
any study day if the number of CCs smoked reported on the sub-
ject's diary card was equal to zero for that day. On study visit days, a
subject was judged compliant if, in addition to having not reported
any CCs smoked, the eCO level was 8 ppm. Use of CCs in the EVP
arm would not generally lead to termination although subjects
were reminded to use only the EVP.
2.7. Bioanalytical methods
2.7.1. Primary outcomes
Haematology samples were analysed using the Siemens Advia
2120® or Siemens Advia 120®. Clinical biochemistry samples were
analysed using the Roche Modular Analytics System®. Urinalysis
parameters were measured using the Siemens Clinitek 500
analyser.
2.7.2. Secondary outcomes
COHb in whole blood samples was assessed with the Roche
Cobas B221 Blood Gas Analyser System using a spectrophotometric
method (Roche, 2009).
The BoE analysis in 24-h urine samples and urine spot samples
was performed by Covance Laboratories, Harrogate, UK, using
validated procedures.For the quantiﬁcation of nicotine equivalents (NEQ), s-phenyl
mercapturic acid (S-PMA), 3-hydroxypropyl mercapturic acid (3-
HPMA) and total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
(NNAL), urine samples were prepared by solid phase extraction,
followed by liquid chromatography coupled with tandem mass
spectrometric detection (LC-MS/MS). For the quantiﬁcation of NEQ
and total NNAL, an enzymatic deconjugation was performed prior
to the extraction, to liberate the glucuronide forms.
For the analysis of PG, samples underwent derivatisation fol-
lowed by liquid-liquid extraction. The centrifuged eluates were
quantiﬁed by liquid chromatography with tandem mass spec-
trometry (LC-MS/MS).
2.8. Statistical analyses
BP, pulse rate, temperature, ECG parameters, clinical laboratory
parameters and questionnaire scores were summarised using
descriptive statistics, including 95% conﬁdence intervals (CIs) for
ECG parameters and questionnaire scores. A Poisson regression
analysiswas performed on the incidence rates of AEs occurring from
Day 1 onwards. The incidence rate is deﬁned as the frequency with
which an AE occurs per subject over the study treatment period.
Estimates of the incidence rate intensity per product and 95% CIs of
these estimates were calculated based on the regression analysis.
Exploratory inferential statistical analyses were performed on lung
function test parameters, BoE and BoBE. A repeated measures
analysis of covariance (RMANCOVA) model was used to compare
changes frombaseline in these parameters between the twogroups.
The model included terms for baseline measurement, sex, age
classiﬁcation, study arm, timepoint, and the interaction between
product and timepoint. No adjustments were made for multiple
comparisons. An exploratory analysis, investigating whether mean
levels of PG in urine was related to the mean number of capsules
used was explored through a scatter plot and regression analysis.
Statistical signiﬁcance was set at a ¼ 0.05 for all analyses and all
statistical tests were conducted using SAS® version 9.3.
3. Results
3.1. Subjects
Out of the 420 planned subjects, a total of 419 were enrolled
onto the study and randomised in a 3:1 ratio to the EVP or CC arm.
Eleven subjects out of the 419 were excluded prior to any product
use. The remaining 408 (Full Analysis Set or FAS) used the study
product at least once. Of these 408 subjects, twenty in the EVP arm
and one in the CC armwere withdrawn from the study, leading to a
total of 387 subjects (94.9% of the FAS) having completed the study
(Fig. 1). In the EVP arm, one subject was withdrawn due to non-
study related death and two due to an AE (see Section 3.3.1 on AEs).
Subjects' characteristics at screening for the FAS are presented in
Table 2, and were similar in both study arms. The majority of
subjects reported using 11e20 CPD, and had moderate nicotine
dependence based on FTND scores. At baseline, subjects in both
study arms had similar CYP2A6 enzyme activities, as shown by
mean (95% CI) trans-3'hydroxycotinine to cotinine plasma con-
centration ratios of 0.297 (0.281e0.314) in the EVP arm and 0.308
(0.279e0.336) in the CC arm.
3.2. Product use and compliance
Subjects in the EVP arm were asked to record the total number
of capsules that they started each day, on a diary card. EVP subjects
were reminded not to use CCs, but if they did, were also asked to
record the number of CC smoked per day.
Fig. 1. Study subjects' ﬂow.
Table 2
Subjects' screening characteristics (Full Analysis Set).
Statistic All subjects Cohort 2
EVP (N ¼ 306) CC (N ¼ 102) EVP (N ¼ 32) CC (N ¼ 8)
Age (years)
Mean ± SD 34.1 ± 10.6 35.1 ± 10.6 34.7 ± 12.2 40.6 ± 15.4
Sex
Males n (%) 168 (54.9%) 58 (56.9%) 22 (68.8%) 6 (75.0%)
Females n (%) 138 (45.1%) 44 (43.1%) 10 (31.3%) 2 (25.0%)
BMI (kg/m2)
Mean ± SD 25.8 ± 3.9 25.3 ± 3.7 25.0 ± 3.1 23.6 ± 4.1
Body weight (kg)
Mean ± SD 75.6 ± 13.7 73.9 ± 13.6 75.4 ± 11.5 71.9 ± 14.8
eCO (ppm)
Mean ± SD 15.8 ± 6.3 16.7 ± 7.3 15.0 ± 5.4 15.1 ± 4.0
Daily cigarette use history
5e10 CPD n (%) 109 (35.6%) 32 (31.4%) 12 (37.5%) 1 (12.5%)
11e20 CPD n (%) 172 (56.2%) 63 (61.8%) 17 (53.1%) 7 (87.5%)
21e30 CPD n (%) 25 (8.2%) 7 (6.9%) 3 (9.4%) 0 (0%)
FTND classiﬁcation
Mild n (%) 91 (29.7%) 30 (29.4%) 13 (40.6%) 2 (25.0%)
Moderate n (%) 173 (56.5%) 55 (53.9%) 14 (43.8%) 6 (75.0%)
Severe n (%) 42 (13.7%) 17 (16.7%) 5 (15.6%) 0 (0%)
ISO nicotine yield of CCs smoked (mg)
Mean ± SD 0.81 ± 0.13 0.81 ± 0.14 0.81 ± 0.15 0.73 ± 0.18
ISO tar yield of CCs smoked (mg)
Mean ± SD 9.2 ± 1.5 9.2 ± 1.5 9.0 ± 1.6 8.3 ± 2.0
Abbreviations: BMI: body mass index; CC: conventional cigarette; CPD: cigarettes per day; eCO: exhaled carbon monoxide as measured by the Smokerlyzer device; EVP: e-
vapour product; FTND: Fagerstroem Test of Nicotine Dependence (mild dependence is deﬁned as a score of 0e3, moderate dependence as a score of 4e6 and severe, 7e10);
ISO: International Organisation for Standardisation; N: number of subjects; SD: standard deviation.
A.S. Cravo et al. / Regulatory Toxicology and Pharmacology 81 (2016) S1eS14 S5Overall, subjects in the EVP arm used a mean (±SEM) of 3.29
(±0.11) to 4.15 (±0.14) capsules per day over the study weeks.Capsule use reﬂected the CC smoking history, with higher CPD
consumption at baseline being associated with higher capsule use
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Capsule use per day during the one-week conﬁnement (Cohort
2) was approximately three times lower than the average use re-
ported by the entire EVP population at the ambulatory visits.
Cohort 2 subjects in the EVP group used a mean (±SEM) of 1.07
(±0.13) capsules per day during the ﬁrst study week.
A total of 123 subjects (40.2%) were classiﬁed as “EVP-
compliant” (see Section 2.6.), and 183 (59.8%) were classiﬁed as
“less-EVP-compliant”. The proportion of EVP-compliant subjects
was highest in the subgroup of subjects with lowest CPD con-
sumption at baseline, and decreased with increasing CPD at base-
line. EVP-compliant subjects did not use more EVP capsules than
less-compliant subjects (the mean daily capsule use was between
3.16 and 4.16 for EVP-compliant subjects, compared with 3.39e4.15
for less EVP-compliant subjects).
The mean self-reported consumption of CCs in the EVP group
was stable over the course of the study, withmeans (±SEM) ranging
from 1.43 (±0.11) to 1.86 (±0.14) CPD at each study week (Fig. 2B).
The consumption of CCs by subjects having lowandmedium CPD at
baseline also remained below 2 CPD. The mean CC consumption
was higher and more variable in the subgroup with high CPD at
baseline (1.64e3.31 CPD over the 12 study weeks). Cohort 2 EVP
subjects reported using a mean (±SEM) of 0.49 (±0.08) CPD during
the conﬁnement period. No trend was observed in Cohort 2 in the
number of CCs smoked during conﬁnement, when stratifying
subgroups by CPD at baseline.
Subjects in the CC armwere asked to record the total number of
CCs that they smoked on each study day, on diary cards. The meanFig. 2. Product consumption by study week. (A) Mean (±SEM) capsules started per day in
(±SEM) CCs smoked per day in the CC group, based on self-reported product use on subjec
consumption. Abbreviations: CC: conventional cigarette; CPD: cigarettes per day; EVP: e-va(±SEM) daily CC use in the CC group over the 12 study weeks
ranged from 12.33 (±0.44) to 14.1 (±0.49) CPD (Fig. 2C). While in
conﬁnement, Cohort 2 subjects reported fewer CCs smoked per day
than the entire CC arm population, with a mean of 3.86 (±0.53)
CPD. None of the subjects randomised to the CC arm in Cohort 2 had
a high CPD consumption at baseline.
3.3. Safety outcomes
3.3.1. Adverse events
In the EVP group, 271 subjects (88.6%) reported a total of 1515
AEs, and in the CC group, 80 subjects (78.4%) reported a total of 225
AEs. The least square mean (LSM) and 95% CI for the AE incidence
rate was at 1.60 (1.55, 1.65) for the EVP group, compared with a rate
of 0.79 (0.66, 0.92) for the CC group. Table 3 shows the number and
percentage of AEs by severity and by relationship with study
product. The proportion of mild, moderate and severe AEs was
similar in both groups, with the majority of reported AEs being of
moderate severity. None of the AEs in the CC group were judged by
the investigator as being related to the product, whereas in the EVP
group, 28.2% of AEs were not suspected to be related to the product;
16.2% were unlikely to be related to the product; 49.6% were
possibly related to the product; 4.7% were probably related and
only 1.3% were judged as almost deﬁnitely related to the product.
Headache, sore throat, desire to smoke, cough, increased
appetite, nasopharyngitis and irritability were very common AEs
(with a frequency, or percentage of subjects reporting the AE,10%)
in the EVP group (Table 4). All common AEs (frequency 1%) thatthe EVP group, (B) mean (±SEM) CCs smoked per day in the EVP group and (C) mean
ts' diary cards. Data is shown for the Full Analysis Set, as well as per baseline cigarette
pour product.
Table 3
Number of AEs (%), by severity and by relationship to product.
EVP (N ¼ 306) CC (N ¼ 102)
Total 1515 (100%) 225 (100%)
SAEs (including deaths) 5 (0.3%) 0
AEs leading to study withdrawal 2 (0.1%) 0
AEs by severity
Mild 449 (29.6%) 64 (28.4%)
Moderate 827 (54.6%) 129 (57.3%)
Severe 239 (15.8%) 32 (14.2%)
AEs by relationship to product
Almost deﬁnitely related 19 (1.3%) 0
Probably related 71 (4.7%) 0
Possibly related 752 (49.6%) 0
Unlikely to be related 246 (16.2%) 0
Not related 427 (28.2%) 225 (100%)
Abbreviations: AE: adverse event; N: number of subjects; SAE: serious adverse
event.
Fig. 3. Overall frequency of AEs (percentage of subjects reporting AEs) in the EVP
group and in the CC group, by study week.
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disturbance in attention (7.2%) are presented in Supplementary
Table S1. In the CC group, the very common AEs were headache
(33.3%) and desire to smoke (12.7%), and common AEs included
sore throat (8.8%), cough (7.8%), nasopharyngitis (7.8%), upper
respiratory tract infection (7.8%), seasonal allergy (5.9%) and hy-
persensitivity (5.9%). The overall frequency of AEs was stable
throughout the study in the CC group between 13.8 and 28.7%, with
a tendency to decrease at EoS. In the EVP group, the frequency
peaked at Week 1 with a value of 59.4%, and steadily decreased
from Week 4, to reach 26.9% at EoS (Fig. 3).
Over the course of the study, ﬁve subjects, all assigned to the
EVP, experienced a total of ﬁve serious AEs (SAEs), none of which
were suspected to be related to the product, or resulted in the
withdrawal of the subject from the study: a puncture wound to the
hand of moderate severity, an acute pancreatitis of moderate
severity, a severe headache, a lobar pneumonia of moderate
severity and one death due to severe cardiac arrhythmia.
One subject in the EVP arm was withdrawn from the study on
Day 47 due to a pregnancy and one subject in the EVP arm was
withdrawn as a precautionary measure on Day 33 due to mild
anaemia detected at Week 2 (3.53  1012/L) and on Day 33
(3.68  1012/L). As per the investigator, the anaemia was not
considered to be related to EVP use, as red blood cell count was
below the reference range (3.99e5.14 1012/L) already at screening
(3.60  1012/L). The red blood cell count was normal at Baseline.
Out of the 1515 AEs reported by subjects using the EVP, 495
(32.7%) AEs, reported by 256 subjects (83.7%), were considered toTable 4
Very common AEs (frequency of 10%) in the EVP group, by system organ class, and fre
EVP (N ¼ 306)
Number of subjects % of subjects Numbe
Respiratory, thoracic and mediastinal disorders
Sore Throat 85 27.8% 119
Cough 52 17.0% 62
Nervous system disorders
Headache 145 47.4% 372
Infection and infestation
Nasopharyngitis 34 11.1% 36
Psychiatric disorders
Desire to smoke 84 27.5% 86
General disorders and administration site conditions
Irritability 33 10.8% 36
Metabolism and nutrition disorders
Increased appetite 43 14.1% 43
Abbreviations: AE: adverse event; N: total number of subjects.be associated with nicotine withdrawal symptoms. After exclusion
of the 495 AEs related to nicotine withdrawal (all in the EVP group),
the incidence rate (LSM [95% CI]) of AEs was still higher in the EVP
group (1.20 [1.14, 1.27]) than in the CC group (0.79 [0.66, 0.92]).3.3.2. Vital signs, clinical laboratory parameters and body weight
There were no clinically signiﬁcant ﬁndings or changes from
baseline in sitting BP, sitting pulse rate, body temperature or 12-
lead ECG parameters at any study visit, with the following excep-
tions: one subject in the EVP group experienced frequent ventric-
ular ectopic beats from Study Day 28, and several subjects in both
groups experienced occurrences of increased heart rate-corrected
QT intervals compared with baseline (24 subjects in EVP group
and 7 subjects in the CC group had occurrences of increased
QTcB > 30 ms and 17 subjects in EVP group and 3 subjects in the CC
group had occurrences of increased QTcF > 30 ms). The ventricular
ectopic beats resolved without corrective treatment and were not
of sufﬁcient concern to withdraw the subject from the study. None
of the changes from baseline in QTcB and QTcF values were above
60ms, and none of the QTcB or QTcF absolute values were above the
threshold of 480 ms, at any visit, for both groups.
No clinically signiﬁcant changes in clinical laboratory parame-
ters, with an onset after the ﬁrst product use, were observed. Uri-
nalysis revealed a urinary tract infection in three subjects (one in CC
arm and two in EVP arm), none of which was considered to bequency of these AEs in the CC group.
CC (N ¼ 102)
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from the study.
Body weight remained stable throughout the study in both
study groups. In the EVP group, body weight ranged from 47.7 to
115.3 kg for a mean (±SD) of 75.8 kg (±14.0) at baseline, and ranged
from 45.8 to 115.3 kg for a mean (±SD) of 76.1 kg (±13.81) at EoS. In
the CC group, mean (±SD) body weight was at 74.0 kg (±13.53) at
baseline and at 74.1 kg (±13.5) at EoS.
3.3.3. Lung function tests
Lung function test parameters at baseline and the changes from
baseline at Week 2, 4, 8 and 12 are shown in Supplementary
Table S2, along with the RMANCOVA analysis results. No clinically
signiﬁcant changes from baseline were observed in any lung
function test parameter, at any study visit. Forced vital capacity
(FVC), forced expiratory volume in one second (FEV1) and forced
expiratory ﬂow 25%e75% (FEF25-75) appeared to decrease during
the course of the study by a maximum of 2.5, 2.4 and 1.5% in the
EVP group, respectively, and by a maximum of 3.2, 3.0 and 5.8% in
the CC group. The RMANCOVA analysis indicated that the decrease
was more pronounced in the CC group compared with the EVP
group for FEV1 at Week 8, and for FEF25-75 at Week 8 and 12. On the
contrary, peak expiratory ﬂow (PEF) appeared to increase during
the course of the study by a maximum of 2.5% in the EVP group and
a maximum of 3.8% in the CC group. These observed changes in PEF
were not different between the two study groups.
The observed increase in PEF was more pronounced in subjects
categorised as less EVP-compliant than those categorised as EVP-
compliant (data not shown). EVP compliance had no inﬂuence on
the observed decreases in the other three parameters.
3.4. Biomarkers of exposure
Fig. 4 shows the mean amounts of NEQ, 3-HPMA, S-PMA, total
NNAL and PG excreted in urine in 24 h (Ae24h), during the course of
the study, for the FAS as well as for Cohort 2 and EVP-compliant
sub-groups. Table 5 shows the changes from baseline in the Ae24h
for the FAS, alongwith the results of the RMANCOVA analysis. In the
EVP group, the Ae24h of NEQ, 3-HPMA, S-PMA, total NNAL were
lower than baseline at all post-baseline timepoints, and as per the
RMANCOVA analysis, these changes from baseline were more
pronounced in EVP subjects compared with CC subjects. Four
weeks after switching, Ae24h for NEQ, 3-HPMA, S-PMA and total
NNAL were lower than at baseline by 33.8, 34.5, 54.5 and 43.5%,
respectively (Table 5). EVP-compliant subjects displayed even
lower levels of these biomarkers than the EVP FAS, at all post-
baseline timepoints (Fig. 4). The Ae24h for NEQ, 3-HPMA, S-PMA
and total NNAL in EVP subjects appeared to increase fromWeek 4 to
EoS, however, at EoS, levels were still lower than at baseline by
25.5, 29.1, 35.1 and 30.9%, respectively.
Cohort 2 EVP subjects, who were monitored for exclusive use of
the EVP for the ﬁrst week of the study, had lower levels of each of
the four BoE than Cohort 2 CC subjects, during thewhole ﬁrst week.
The decreases were evident from Day 2 (Fig. 4). At baseline, Cohort
2 subjects from both groups displayed lower levels of NEQ, 3-
HPMA, S-PMA and total NNAL than the FAS. The level of these
BoE increased after the conﬁnement week, to reach similar levels as
the FAS at Week 4, 8 and 12.
Regarding PG, the Ae24h in CC subjects was similar to baseline
during the whole study. By contrast, the urine level of PG increased
in EVP subjects from Day 2 (Cohort 2), and continued to increase at
Week 4, where it was higher than baseline by 182.5% (FAS). The PG
increasewas proportional to the number of EVP capsules used (data
not shown). From Week 4 to EoS, PG appeared to decrease in the
EVP group, but was still higher than baseline by 119.2%. As per theRMANCOVA analysis, the PG level was signiﬁcantly higher in EVP
subjects compared with CC subjects at all post-baseline timepoints
(Table 5).
As with the four BoE measured in urine, blood COHb and eCO
rapidly decreased in subjects switching to use the EVP. At baseline,
eCO was at 20.3 ppm (±8.4) in EVP subjects and at 21.3 ppm (±9.2)
in CC subjects. In the EVP group, eCO levels dropped to 7.4 ppm at
Week 1 and were between 7.6 and 9.0 ppm from Week 2 to EoS
(eCO levels in non-smokers are typically 6 ppm (Bedfront, 2016)).
In the CC group, eCO remained at levels close to baseline during the
whole study (21.3e23.3 ppm).
At baseline, COHb was at a mean level (95% CI) of 6.79% (6.60,
6.98) and decreased to 3.61% (3.50, 3.72) on Day 2 (in Cohort 2 EVP
subjects). COHb was subsequently measured in EVP subjects at
mean levels ranging from 4.06% (3.92, 4.19) to 4.37% (4.22, 4.52)
from Week 1 to EoS (COHb levels in non-smokers are typically
<2.0% (Buchelli Ramirez et al., 2014)). The mean COHb level in CC
subjects remained between 6.70% (6.35, 7.05) and 6.94% (6.55, 7.32)
throughout the study. EVP-compliant subjects had similar COHb
levels to the whole EVP population.
3.5. Biomarkers of biological effect
The mean levels of haemoglobin, white blood cell count (WBC),
low-density lipoprotein (LDL) and high-density lipoprotein (HDL)
cholesterol at baseline and the changes from baseline at Week 2, 4,
8 and 12 are shown in Supplementary Table S3, along with the
RMANCOVA analysis results. None of the observed changes from
baseline in those parameters were judged as being clinically
signiﬁcant.
Mean haemoglobin levels appeared to be lower than at baseline
during the course of the study by a maximum of 2.9% in the EVP
group and 2.1% in the CC group. The changes from baseline in
haemoglobin levels were not different in EVP subjects compared
with CC subjects (Table S3). Similar patterns to haemoglobin were
observed for haematocrit (PVC) and red blood cell count (RBC; data
not shown).
Mean WBC appeared to be lower than at baseline during the
study in the EVP group, by a maximum of 6.6%, whereas in the CC
group, no consistent changes were observed. The RMANCOVA
analysis indicated that at Week 8, the mean WBC was signiﬁcantly
lower in the EVP group compared with the CC group (Table S3).
EVP-compliant subjects displayed greater decreases from baseline
in mean WBC than less EVP-compliant subjects (not shown).
Regarding cholesterol, the mean level of HDL cholesterol
remained stable throughout the study in the EVP group, whereas in
the CC group, it appeared to decrease during the study by a
maximum of 3.5%. The RMANCOVA analysis indicated that at Week
4 and 8, the observed changes were signiﬁcantly greater in the CC
group compared with the EVP group (Table S3). Mean LDL choles-
terol levels appeared to be lower than at baseline in both groups
during the study. However, the decreases were small (maximum
3.0% in the EVP group and maximum 1.2% in the CC group), and
according to the RMANCOVA analysis, they were not different be-
tween the two study groups. Total cholesterol changes (data not
shown) were similar to those observed for LDL cholesterol, and
none of the changes that were observed during the study were
remarkably different between the two study groups. EVP compli-
ance did not appear to inﬂuence the changes of cholesterol levels in
any direction (data not shown).
3.6. Subjective effects
At baseline, meanMWS-R extended total scores were similar for
both study groups (4.3 for EVP subjects and 4.8 for CC subjects). For
Fig. 4. Mean (±SEM) amounts of selected biomarkers of exposure excreted in urine in 24 h (Ae24h) for all subjects and for Cohort 2 subjects (grey area). Abbreviations: CC:
conventional cigarette; EVP: e-vapour product; 3-HPMA: 3-hydroxypropyl mercapturic acid; NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NEQ: nicotine equivalents; PG:
propylene glycol; SEM: standard error of the mean; S-PMA: s-phenyl mercapturic acid.
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subjects, scores increased to a mean (±SEM) of 10.2 (±0.5) at Week
1 (Fig. 5A), indicating that EVP subjects experienced more pro-
nounced withdrawal symptoms at Week 1, than CC subjects. At
Week 1, MWS-R scores in EVP subjects were higher than at baselineby 139.5%. The scores for EVP subjects subsequently decreased
steadily along studyweeks to reach 5.8 (±0.4) at EoS (higher than at
baseline by 39.5%). The MWS-R core total scores showed similar
trends to the extended total scores (not shown).
QSU-Brief total scores were similar for the two groups at
Table 5
Changes from baseline in the amount of biomarkers of exposure excreted in 24 h in urine (Ae24h) at Week 4, 8 and 12, and between-group comparisons of the changes from
baseline, for the FAS.
Changes from baseline RMANCOVA analysis of the changes from baseline
EVP CC EVP CC Difference (EVP - CC)
n Mean % change 95% CI for the mean n Mean % change 95% CI for the mean LSM LSM LSM difference 95% CI for the LSM difference
NEQ (mg)
Baseline 305 9.9 n/a 9.2, 10.6 102 10.1 n/a 8.9, 11.4 n/a n/a n/a n/a
Week 4 295 3.4 33.3 4.0, 2.7 101 0.1 1.0 1.1, 0.9 3.1 0.3 3.4 ¡4.5, -2.4
Week 8 282 2.9 29.3 3.6, 2.3 100 0.3 3.0 0.7, 1.2 2.7 0.7 3.4 ¡4.4, -2.4
Week 12 284 2.5 25.3 3.2, 1.9 100 0.6 5.9 1.7, 0.6 2.4 0.2 2.2 ¡3.2, -1.1
3-HPMA (ug)
Baseline 305 1820 n/a 1680, 1950 102 1710 n/a 1510, 1900 n/a n/a n/a n/a
Week 4 295 628 34.5 762, 495 101 215 12.6 49, 381 554 217 771 ¡984, -558
Week 8 282 590 32.4 737, 442 100 192 11.2 7, 378 527 191 719 ¡933, -505
Week 12 284 530 29.1 678, 382 100 96 5.6 128, 320 471 88 559 ¡773, -345
S-PMA (ng)
Baseline 305 3820 n/a 3450, 4190 102 3660 n/a 3090, 4220 n/a n/a n/a n/a
Week 4 295 2080 54.5 2420, 1740 101 114 3.1 267, 494 1988 103 2091 ¡2585, -1597
Week 8 282 1800 47.1 2130, 1470 100 144 3.9 509, 220 1754 166 1588 ¡2085, -1091
Week 12 284 1340 35.1 1740, 943 100 31 0.8 449, 512 1307 19 1325 ¡1822, -829
Total NNAL (ng)
Baseline 305 246 n/a 222, 269 102 244 n/a 202, 286 n/a n/a n/a n/a
Week 4 295 106 43.1 127, 85 101 18 7.4 6, 43 102 20 122 ¡155, -90
Week 8 282 95 38.5 117, 72 100 15 6.1 9, 40 93 17 110 ¡142, -77
Week 12 284 76 30.9 98, 54 100 6 2.5 26, 38 75 8 83 ¡116, -51
PG (mg)
Baseline 305 6.3 n/a 5.4, 7.2 102 7.4 n/a 5.0, 9.8 n/a n/a n/a n/a
Week 4 295 11.5 182.5 8.1, 15 101 0.5 6.8 2.5, 1.4 11.1 0.3 11.4 6.0, 16.7
Week 8 282 10.5 166.7 7.2, 13.8 100 0.03 0.4 2.7, 2.7 9.8 0.3 9.5 4.1, 14.9
Week 12 284 7.5 119.2 4.6, 10.4 100 0.2 2.7 2.7, 2.3 6.8 0.1 6.8 1.4, 12.2
Note: The absolute value is given for Baseline. The LSM of the changes from baseline for each product at each timepoint was calculated, alongwith the LSMs difference (EVP-CC)
and the 95% CI for the difference, using a RMANCOVA model. Cases where the 95% CI for the difference does not include 0.0 are highlighted in bold.
Abbreviations: CC: conventional cigarette; CI: conﬁdence interval; EVP: e-vapour product; LSM: least square mean; 3-HPMA: 3-hydroxypropyl mercapturic acid; NNAL: 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NEQ: nicotine equivalents; PG: propylene glycol; S-PMA: s-phenyl mercapturic acid.
Fig. 5. (A) Revised Minnesota Nicotine Withdrawal Scale (MWS-R) mean (±SEM) extended total scores and (B) Brief Questionnaire of Smoking Urges (QSU-Brief) mean (±SEM) total
scores at each study visit. The y-axes do not reﬂect the whole score ranges. Abbreviations: CC: conventional cigarette; EVP: e-vapour product; SEM: standard error of the mean.
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31.2 for CC subjects). Scores appeared to steadily decrease
throughout the study for both study groups (Fig. 5B), indicating a
decrease in desire to smoke during the course of the study. At EoS,
scores were lower than at baseline by 28.6% for EVP subjects and by
33.3% for CC subjects. QSU-Brief Factor 1 and Factor 2 scores
showed similar trends to the total scores (not shown).
Subjective effects for Cohort 2 subjects are shown in
Supplementary Fig. S4. During the ﬁrst study week in conﬁnement,
QSU-Brief total scores and MWS-R extended total scores reportedby Cohort 2 subjects using CCs appeared to decrease compared
with baseline, whereas they appeared to slightly increase for sub-
jects using the EVP. On Day 5, the mean (±SEM) MWS-R score was
6.8 (±1.2), and QSU-Brief score was 26.70 (±2.90) for Cohort 2 EVP
subjects. When EVP subjects got out of conﬁnement, the mean
MWS-R score decreased to 2.7 (±0.5) atWeek 1, and themean QSU-
Brief score decreased to 18.20 (±1.80). Both scores for Cohort 2 EVP
subjects subsequently followed the same trend as Cohort 1 EVP
subjects, MWS-R score being however lower for Cohort 2 than for
Cohort 1 subjects.
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This study was designed as follow-up to a previous investigation
that evaluated nicotine PK, the short-term safety proﬁle and sub-
jective effects of an EVP used by smokers for four days in clinical
conﬁnement (Walele et al., 2016a, 2016b). The previous study
showed that the EVP had a similar PK and short-term safety proﬁle
to a licensed nicotine inhalator. For the current study, the primary
objective was to evaluate the safety proﬁle of smokers switching to
use the same EVP device for a period of 12 weeks. This evaluation
also included the determination of the level of selected BoE in
urine, the level of selected BoBE in blood, smoking desire and
withdrawal symptoms measured by questionnaires. For compari-
son purposes, a group of subjects who continued using their usual
CC brand for 12 weeks was also included.
During the course of the study, there were no withdrawals due
to product-related AEs and only 1.3% of all AEs reported by subjects
using the EVP were judged by the Principal Investigator as almost
deﬁnitely related to the product. Subjects using the EVP reported
AEs primarily within the ﬁrst week after product switch and the
frequency of AEs steadily subsided from the second week of
product use. Moreover, AEs judged by the Principal Investigator as
being related to nicotine withdrawal were identiﬁed, and accoun-
ted for a third of all AEs in the EVP group. Overall, there were no
clinically signiﬁcant ﬁndings or changes frombaseline for any of the
clinical laboratory evaluations, vital signs, lung function tests or
ECG parameters during the course of this study.
The most common AE in both study groups was headache (re-
ported by 33.3% of subjects in the CC group and by 47.4% of subjects
in the EVP group). The other common AEs, reported by 10% of
subjects, in the EVP group, in order of frequency were: sore throat,
desire to smoke, cough, increased appetite, nasopharyngitis and
irritability. Of these, desire to smoke, sore throat, cough and
nasopharyngitis were also commonly reported by subjects who
continued smoking CCs (refer to Table S1 for a complete list of
common AEs). Such AEs may be expected in subjects using a new
type of inhaled product, with frequency decreasing towards EoS
possibly due to an acclimation effect. Headache and other AEs
related to the respiratory and gastrointestinal systems as reported
here are commonly experienced in CC smokers switching to use
EVPs (including in real-life settings) (Bullen et al., 2010; Cantrell,
2014; Chen, 2013; D'Ruiz et al., 2015; Polosa et al., 2011, 2014) or
nicotine replacement therapies in the form of nicotine inhalers or
sprays (Bolliger et al., 2000; Kralikova et al., 2009; Moyses et al.,
2015; Tonnesen et al., 2012). None of the ﬁve SAEs experienced
by EVP subjects during the course of the study were judged by the
investigator as being related to the EVP. One subject in the EVP
group died from severe cardiac arrhythmia on Study Day 42, and
was conﬁrmed post-mortem. ECG and vital signs were considered
normal on Day -1, Day 14 and Day 28. The investigator used The
European Society of Cardiology's online Heartscore tool to assess
the subject's total cardiovascular disease (CVD) mortality risk on
study Day -1 (ESC, 2016). Based on the subject's age (45 years),
gender (male), cholesterol levels (total at 4 mmol/L and HDL
cholesterol at 1.1 mmol/L), systolic BP (124 mmHg), and smoking
habit (11e20 CPD), the subject had a total CVD risk of 1% (10-year
risk mortality). As per the investigator, the death was not related
to EVP use.
Body weight was not affected by EVP use (despite increased
appetite being reported by 14.1% of subjects in the EVP group,
compared with 1.0% in the CC group). In another study where
smokers of CCs switched to an EVP and were followed-up for 52
weeks, body weight gain at 12 and 24 weeks was small (2.4 kg and
2.9 kg), but signiﬁcantly higher than at baseline only in subjects
who completely quit CCs. Interestingly, 12 months after the switchto EVP, weight gain was reversed, and body weight was no longer
different from baseline. Body weight remained stable in subjects
who reduced, but did not completely stop their consumption of CCs
(Russo et al., 2016). It thus appears that EVPs at least partially
prevent the body weight gains typically associated with smoking
cessation.
With regards to lung function, the observed changes in
spirometry parameters (FVC, FEV1, FEF25-75 and PEF) were not of
clinical relevance. None of the FEV1 values were below the
threshold of 80% of the predicted value. Moreover, those changes
were more pronounced in the CC group than in the EVP group. In
the light of these ﬁndings, it is possible that subjects modiﬁed their
breathing pattern for spirometry tests during the study. Unpub-
lished data from Polosa et al., suggests that improvements in FEF25-
75 are observed in smokers of CCs after three months from
switching to an EVP (Polosa, 2015). In order to adequately
discriminate between a true and false product related effect, longer
studies with a greater number of subjects would be required.
Moreover, more sensitive lung function testingmethodologies than
spirometry could be used. In short-term studies, signiﬁcant acute
pulmonary effects after EVP use were detected by impulse oscill-
ometry, while spirometry did not reveal any changes (Flouris et al.,
2013; Vardavas et al., 2012).
Current evidence from published literature indicates that CC
smokers have signiﬁcantly higher blood levels of WBC and LDL
cholesterol and lower blood levels of HDL cholesterol than non-
smokers (Frost-Pineda et al., 2011; Lowe et al., 2009; Ludicke
et al., 2015). HDL cholesterol has been shown to increase after
smoking cessation (Maeda et al., 2003), whereas haemoglobin,
WBC and RBC are shown to decrease (Bain et al., 1992). An increase
in HDL levels has purportedly been associated with decreased
cardiovascular disease risks (Kapur et al., 2008). In our study, no
consistent changes were observed in these BoBE, therefore no ﬁrm
conclusions could be drawn. However, HDL cholesterol levels
appeared to decrease in CC subjects, whereas in EVP subjects they
appeared to remain stable. EVP users also appeared to have greater
decreases in WBC, haemoglobin and LDL cholesterol than CC
smokers, which is consistent with changes observed during
smoking cessation.
Regarding nicotine exposure, the level of NEQs in the urine of CC
subjects remained stable during the whole study, as expected.
NEQs in urine decreased rapidly in EVP subjects (from Day 2 in
Cohort 2), and were signiﬁcantly lower than the CC group at Week
4, 8 and 12. NEQ levels were even lower for the EVP-compliant
subgroup, with an approximate 2-fold decrease compared with
baseline. In our previous PK study, the mean maximum plasma
nicotine concentration (Cmax) in CC smokers switching to the EVP
with 2% nicotine containing e-liquids was 2.5 ng/ml for unﬂavoured
e-liquids and 3.6 ng/ml for ﬂavoured e-liquids. This was reached in
7e10 min, compared with a Cmax of 21.2 ng/ml reached in 3 min for
CCs (Walele et al., 2016a). A decrease in the level of NEQs in the
urine of smokers switching to the EVP was therefore expected in a
study population consisting of established smokers of CCs with
very limited prior experience with EVPs (at screening, only three
out of all subjects declared using EVPs). Such a decrease was also
observed by Hecht et al. (2015) in exclusive EVP users who had
switched for a period between 2 and 36months; the reported urine
nicotine level was 1.5-fold lower in these EVP users compared with
regular smokers of CCs.
In EVP subjects, the observed decrease in urine NEQ after
product switch coincided with an increase in nicotine withdrawal
symptoms (by 139.5% at Week 1), as measured by the MWS-R
questionnaire. This was expected in CC smokers switching to a
product that was shown to deliver less nicotine to plasma than CCs
(Walele et al., 2016a). After two weeks, the symptoms subsided,
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tobacco use indicating a resolution of withdrawal effects. At EoS,
the mean MWS-R score for EVP subjects was still higher than at
baseline, but only by 39.5%. In a longer-term published study,
product satisfaction (measured by a questionnaire on perception
and liking of the product) was assessed as moderate in smokers
switching to an EVP for 12e52 weeks, however, nicotine with-
drawal related side effects were not frequently reported
(Caponnetto et al., 2013). In that study, both product satisfaction
and withdrawal side effects were similar in subjects using an EVP
with and without nicotine indicating that withdrawal effects are
complex symptoms most probably associated with additional fac-
tors besides nicotine. In our previous investigation, nicotine with-
drawal symptoms were also reduced to a similar extent with and
without nicotine, when the EVP was used by CC smokers after
overnight smoking abstinence (Walele et al., 2016b).
Despite 27.5% of subjects in the EVP group reporting desire to
smoke compared with 12.7% in the CC group, no differences were
observed in QSU-Brief scores between the two study groups. This
indicates that smokers of CC switching to use the EVP in real-life
settings do not experience a higher degree of smoking urges than
smokers of CCs continuing to smoke their usual CC brand. During
the conﬁnement period, Cohort 2 CC subjects reported lower QSU-
Brief scores than EVP subjects. In conﬁnement, EVP subjects were
told to refrain from smoking CCs, whereas during the rest of the
study, designed to reﬂect real-life settings, EVP subjects were free
to smoke a CC if they experienced moderate or severe desire to
smoke. In addition, desire to smoke effects, similarly to other re-
ported AEs, may appear early after product switch, and subside
from the second week of EVP use, due to increasing product
acceptance. At baseline, QSU-Brief scores were higher than at any
other study visits for both study groups. Another confounding
factor relates to the possibility of subjects overestimating their
desire to smoke when ﬁlling the QSU-Brief questionnaire for the
ﬁrst time, despite not being abstinent from smoking.
Unsurprisingly, PG exposure, as shown by urine excretion levels,
increased rapidly and was signiﬁcantly higher in EVP subjects than
in CC subjects at all timepoints. Although PG is used as a humectant
in CCs, levels are greater in EVP e-liquids due to its use as an
excipient. The levels of the other investigated urine BoE, i.e. 3-
HPMA, S-PMA and total NNAL were observed to decrease in sub-
jects switching to the EVP (by up to 54.5%), with a similar pattern
for subgroups to that observed for NEQs. Such decreases may be
expected knowing that closed system EVPs similar to the one tested
here, generate several lower orders of magnitude of volatiles
(including benzene), carbonyls (including acrolein) and TSNAs per
puff of aerosol than CCs (Goniewicz et al., 2014; Lauterbach et al.,
2012; Tayyarah and Long, 2014). When looking at study groups in
general, it clearly appears that the levels of these BoE decrease with
decreasing CC consumption. CC smokers had the highest levels,
followed by the EVP FAS (who reported smoking means of 1e2 CPD
throughout the study) and followed by EVP-compliant subjects
who were abstinent from CCs for over 80% of study days. This
observation is in linewith ﬁndings from others, that urine BoE from
toxicants present in CC smoke, including 3-HPMA, S-PMA and total
NNAL, decrease with decreasing CPD in a dose-dependent manner
(O'Connell et al., 2016; Theophilus et al., 2015). Our results are also
in broad agreement with ﬁndings from Hecht et al. (2015) and
McRobbie et al. (2015). The former found that exclusive EVP users
had approximately 65-fold, 5-fold and 10-fold lower urine levels of
total NNAL, 3-HPMA and S-PMA, respectively, than CC smokers
(Hecht et al., 2015), and the latter found that CC smokers switching
to using an EVP in a dual mode had 2.5-fold less 3-HPMA in urine
than at baseline (McRobbie et al., 2015). In a short-term conﬁne-
ment study by O'Connell et al. (2016), smokers of CCs switching toexclusive EVP use reported greater than 80%, 90% and 60% de-
creases of 3-HPMA, S-PMA and NNAL respectively in urine
compared with baseline, which was very similar to decreases
observed in smokers completely quitting tobacco products. For
comparison, Cohort 2 subjects in our study reported a 32%, 78% and
55% reduction in these three BoE, respectively, after ﬁve days in
conﬁnement. These reductions are not as great as those observed in
the O'Connell et al. study, mainly because Cohort 2 subjects dis-
played lower levels of these urine BoEs at baseline. The baseline
levels of all ﬁve investigated BoE were lower for Cohort 2 subjects
(both arms) than for Cohort 1 subjects. This may be due to the small
number of subjects in Cohort 2, of which very few (only three) had a
high baseline CPD consumption (21e30 CPD). Themagnitude of the
decrease in exposure to toxicants could be even greater in subjects
with a high CC consumption history, switching to use exclusively
the EVP. It should also be noted that from Day -2 until the end of
conﬁnement, Cohort 2 subjects received a diet without any grilled
or smoked meat.
When Cohort 2 subjects got out of conﬁnement, the level of BoE
increased in both study groups to levels similar to Cohort 1 sub-
jects, which was most probably due to concomitant use of CCs in
the EVP group, and an increase of CC consumption in the CC group.
Moreover, when Cohort 2 EVP subjects got out of conﬁnement, a
decrease in MWS-R and QSU-Brief scores was observed, which also
indicates that subjects may have consumed CCs. Towards EoS, the
level of NEQs, 3-HPMA, S-PMA and total NNAL in urine appeared to
increase in EVP subjects, which could be explained by EVP subjects
smoking more CCs than reported on their diary cards when
approaching the end of the study.
Our results, when taken together with other studies reported in
the literature, suggest that for acrolein, benzene and NNK, reduced
emissions in the aerosol translate into reduced exposure in
smokers switching to EVPs, and that this effect can be observed in a
short period of time after the switch. In our study, the level of these
three BoE showed similar trends to the level of NEQ throughout the
study and for all study groups. This study does not inform, however,
on themagnitude of exposure to different chemicals in experienced
EVP users, who were shown to intake as much nicotine as CC
smokers (Etter, 2016). Additional studies should be performed in
order to assess if, and how exposure to such chemicals correlates
with exposure to nicotine in EVP users.
For future work, a wider selection of measured BoEs should be
addressed, alongside formaldehyde and acetaldehyde quantiﬁca-
tion or any related biomarker. Although these were initially
included in our analysis plan, due to a sample instability issue,
these BoE could not be quantiﬁed. In addition, this study was
designed to detect AEs occurring at a frequency of 1%, and not to
detect differences between the two arms. Therefore, any observed
differences between groups should be interpreted with caution.
Finally, a longer study period than the 12-week exposure per-
formed here would provide a better insight at detecting AEs that
increase in frequency or severity with time (ICH, 1994).
5. Conclusions
In this study, we have demonstrated that no clinically relevant,
product-related safety ﬁndings were observed for smokers of CCs
switching to an EVP for 12 weeks under real-life settings. AEs re-
ported by subjects switching to the EVP occurred primarily within
the ﬁrst week after switching, and only 1.3% of all AEs reported
were considered to be almost deﬁnitely related to the product. Up
to a third of the all reported AEs in the EVP group were related to
nicotine withdrawal symptoms, which were observed to decrease
after the ﬁrst two weeks from product switch. EVP use was asso-
ciated with signiﬁcant decreases in exposure to nicotine and other
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smoke. Changes were also observed in the level of WBC, haemo-
globin, RBC and LDL cholesterol, which although minor, were
consistent with those observed after smoking cessation. The data
presented in this study shows the potential that EVPs may offer to
smokers looking for an alternative to CCs.
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